936343-08-7

Basic information

• Product Name: 5-bromo-2-(4-fluoro-benzyloxy)-pyridine
• Synonyms: 5-bromo-2-(4-fluoro-benzyloxy)-pyridine
• CAS NO: 936343-08-7
• Molecular Formula: C₁₂H₉BrFNO
• Molecular Weight: 282
• Mol File: 936343-08-7.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-bromo-2-(4-fluoro-benzyloxy)-pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-2-(4-fluoro-benzyloxy)-pyridine(936343-08-7)
• EPA Substance Registry System: 5-bromo-2-(4-fluoro-benzyloxy)-pyridine(936343-08-7)

Safety Data

• Hazardous Substances Data: 936343-08-7(Hazardous Substances Data)

Upstream product

• 624-28-2 2,5-dibromopyridine 
• 459-56-3 4-fluorobenzylic alcohol 
• 766-11-0 5-bromo-2-fluoropyridine 
• 13466-38-1 5-bromopyridin-2(1H)-one 
• 459-46-1 4-Fluorobenzyl bromide 

Downstream Products

• 936343-09-8 6-(4-fluoro-benzyloxy)-pyridine-3-carbaldehyde 

Relevant articles and documents

ANTIBACTERIAL COMPOUNDS

The present invention relates to compounds of general formula (II),to compositions comprising these compounds and to methods of treating Enterobacteriaceae bacterial diseases and infections using the compounds. The compounds find application in the treatment of infection with, and diseases caused by, Enterobacteriaceae.

Boronic species as promising inhibitors of the Staphylococcus aureus NorA efflux pump: Study of 6-substituted pyridine-3-boronic acid derivatives

In response to the extensive use of antibiotics, bacteria have evolved numerous mechanisms of defense against antimicrobial agents. Among them, extrusion of the antimicrobial agents outside the bacterial cell through efflux pumps is a major cause of concern. At first limited to one or few structurally-related antibiotics, bacterial resistance have then progressed towards cross-resistance between different classes of antibiotics, leading to multidrug-resistant microorganisms. Emergence of these pathogens requires development of novel therapeutic strategies and inhibition of efflux pumps appears to be a promising strategy that could restore the potency of existing antibiotics. NorA is the most studied chromosomal efflux pump of Staphylococcus aureus; it is known to be implied in resistance of Methicillin-resistant S. aureus (MRSA) strains against a wide range of unrelated substrates, including hydrophilic fluoroquinolones. Starting from 6-benzyloxypyridine-3-boronic acid I that we previously identified as a potential inhibitor of the NorA efflux pump against the NorA-overexpressing S. aureus 1199B strain (SA1199B), we describe here the synthesis and biological evaluation of a series of 6-(aryl)alkoxypyridine-3-boronic acids. 6-(3-Phenylpropoxy)pyridine-3-boronic acid 3i and 6-(4-phenylbutoxy)pyridine-3-boronic acid 3j were found to potentiate ciprofloxacin activity by a 4-fold increase compared to the parent compound I. In addition, it has been shown that both compounds promote Ethidium Bromide (EtBr) accumulation in SA1199B, thus corroborating their potential mode of action as NorA inhibitors.